AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12583553 — intervention group
Group type: EXPERIMENTAL
Intervention: meropenem 500 mg i.v. t.i.d.
Number of subjects: 204
Study 12583553 — intervention group
Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin 500 mg i.v. t.i.d.
Number of subjects: 204
Study 12583553 — intervention group
Group type: EXPERIMENTAL
Intervention: clarithromycin 500 mg + ceftriaxone 1 g i.v. b.i.d.
Number of subjects: 204
Study 12583553 — intervention group
Group type: EXPERIMENTAL
Intervention: clarithromycin 500 mg + amikacin 250 mg i.v. b.i.d.
Number of subjects: 204
Study 10404804 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 5 mg
Number of subjects: 1202
Study 8527541 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 177
Study 8527541 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin plus Clindamycin (T/C)
Number of subjects: 177
Study 2316078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin treatment without nephroprotection
Number of subjects: 0
Study 2316078 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin treatment with nephroprotective amino acids
Number of subjects: 0
Study 2316078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast media during urography
Number of subjects: 0
Study 2316078 — intervention group
Group type: COMPARATOR
Intervention: Non-ionic contrast media during urography
Number of subjects: 0
Study 2316078 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pyelonephritis
Number of subjects: 0
Study 2316078 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave lithotripsy
Number of subjects: 0
Study 2316078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower urinary tract infections
Number of subjects: 0
Study 6938012 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate (Estracyt)
Number of subjects: 212
Study 6938012 — intervention group
Group type: COMPARATOR
Intervention: polyestradiol phosphate and ethinyl estradiol
Number of subjects: 212
Study 6938012 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 212
Study 6938012 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous cardiovascular disease
Number of subjects: 212
Study 31888713 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimin decoction (BMD)
Number of subjects: 108
Study 31888713 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone nasal spray and loratadine tablets
Number of subjects: 108
Study 27388441 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year intervention focusing on increasing physical activity (PA) and fruit and vegetable intake (FVI), decreasing screen media use (SMU) and soft drink consumption (SDC)
Number of subjects: 525
Study 25531240 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based care (administered by a dedicated research nurse)
Number of subjects: 16
Study 25531240 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 16
Study 25531240 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based care
Number of subjects: 16
Study 23408834 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 56
Study 23408834 — intervention group
Group type: COMPARATOR
Intervention: Premalignant and early stages of myeloma
Number of subjects: 56
Study 23408834 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced stages of myeloma
Number of subjects: 56
Study 23408834 — intervention group
Group type: EXPERIMENTAL
Intervention: DNMT3A underexpression
Number of subjects: 56
Study 23408834 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypomethylating agents
Number of subjects: 56
Study 21220074 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg oral hydrocortisone
Number of subjects: 60
Study 21220074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19371934 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine plus terazosin (5 mg Amlodipine + 2 mg terazosin)
Number of subjects: 355
Study 19371934 — intervention group
Group type: COMPARATOR
Intervention: Terazosin (2 mg)
Number of subjects: 355
Study 19371934 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg)
Number of subjects: 355
Study 17376205 — intervention group
Group type: EXPERIMENTAL
Intervention: Local heat therapy by radiofrequency (RF) at 50 degrees C for 30 s once weekly for 4 weeks
Number of subjects: 117
Study 17376205 — intervention group
Group type: COMPARATOR
Intervention: Intralesional injection of meglumine antimoniate once weekly for 4 weeks
Number of subjects: 117
Study 15456084 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverset (RVT) 10 mg
Number of subjects: 18
Study 15456084 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverset (RVT) 10-200 mg
Number of subjects: 18
Study 15456084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11432083 — intervention group
Group type: EXPERIMENTAL
Intervention: POLY-Nag (N-acetyl-D-glucosamine)
Number of subjects: 0
Study 11432083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10968096 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.625 mg and Metoclopramide 10 mg (Group II)
Number of subjects: 80
Study 10968096 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 0.625 mg (Group I)
Number of subjects: 80
Study 8440364 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan-prednisone (MP) therapy started at the time of diagnosis
Number of subjects: 50
Study 8440364 — intervention group
Group type: COMPARATOR
Intervention: deferred therapy where MP was started at the time of disease progression
Number of subjects: 50
Study 3532298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg at night
Number of subjects: 197
Study 3532298 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 197
Study 31373520 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-delivered cognitive behavior therapy (ICBT) for panic disorder
Number of subjects: 143
Study 27631776 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain
Number of subjects: 469
Study 27631776 — intervention group
Group type: COMPARATOR
Intervention: No Drain
Number of subjects: 469
Study 25888515 — intervention group
Group type: COMPARATOR
Intervention: Cont (no drugs)
Number of subjects: 9
Study 25888515 — intervention group
Group type: EXPERIMENTAL
Intervention: Prop (propranolol)
Number of subjects: 9
Study 25888515 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyc (glycopyrrolate)
Number of subjects: 9
Study 25888515 — intervention group
Group type: EXPERIMENTAL
Intervention: Prop + Glyc
Number of subjects: 9
Study 23867718 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Ophthalmology Clinic (VOC)
Number of subjects: 188
Study 23867718 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 188
Study 21443960 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02(A) malaria vaccine
Number of subjects: 2022
Study 19318990 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT)
Number of subjects: 112
Study 19318990 — intervention group
Group type: COMPARATOR
Intervention: Group support and attention (GSA)
Number of subjects: 112
Study 17188040 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 108
Study 17188040 — intervention group
Group type: COMPARATOR
Intervention: SICS
Number of subjects: 108
Study 15093992 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day) for 30 days
Number of subjects: 43
Study 11250999 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose alkylating agents (HDC) with autologous cellular support after doxorubicin-based therapy (AFM)
Number of subjects: 425
Study 11250999 — intervention group
Group type: COMPARATOR
Intervention: HER-2 measured by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH)
Number of subjects: 425
Study 11250999 — intervention group
Group type: EXPERIMENTAL
Intervention: HER-2 ECD
Number of subjects: 425
Study 9385483 — intervention group
Group type: EXPERIMENTAL
Intervention: mibefradil 100 mg
Number of subjects: 239
Study 9385483 — intervention group
Group type: COMPARATOR
Intervention: diltiazem CD 360 mg
Number of subjects: 239
Study 9385483 — intervention group
Group type: EXPERIMENTAL
Intervention: mibefradil
Number of subjects: 239
Study 9385483 — intervention group
Group type: COMPARATOR
Intervention: diltiazem CD
Number of subjects: 239
Study 8487048 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard regimen (S) - six injections of triple intrathecal chemotherapy (TIC) consisting of methotrexate (MTX), hydrocortisone (HC), and cytarabine (ara‐C) during intensification and at every‐8‐week intervals for 17 additional doses.
Number of subjects: 1152
Study 8487048 — intervention group
Group type: COMPARATOR
Intervention: Standard and MTX pulses (SAM) - six TICs during intensification, substituted with every‐8‐week pulses of intermediate‐dose parenteral methotrexate (IDM; 1 g/m2) for the 17 maintenance TIC injections, with a low‐dose intrathecal (IT) MTX boost with the first four maintenance IDM pulses.
Number of subjects: 1152
Study 3440390 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based screening for hypertension
Number of subjects: 11386
Study 3440390 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic screen for confirmation of elevated BP
Number of subjects: 11386
Study 3440390 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP measurements
Number of subjects: 11386
Study 2403586 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2 1-g capsules with each meal for 12 weeks)
Number of subjects: 33
Study 2403586 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (2 1-g capsules with each meal for 12 weeks)
Number of subjects: 33
Study 1093506 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (0.3 mg/kg)
Number of subjects: 24
Study 1093506 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.25 mg/kg)
Number of subjects: 24
Study 1093506 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.05 mg/kg)
Number of subjects: 24
Study 1093506 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (high dose)
Number of subjects: 24
Study 1093506 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 24
Study 30541021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST)
Number of subjects: 44
Study 27911486 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual PSA tests for 6 years and digital rectal examinations for 4 years (Intervention arm)
Number of subjects: 76383
Study 27911486 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no organized screening)
Number of subjects: 76383
Study 27911486 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual PSA tests for 6 years (Intervention arm)
Number of subjects: 76383
Study 25935165 — intervention group
Group type: EXPERIMENTAL
Intervention: Early atrial fibrillation (EAF) within 3 months post-procedure
Number of subjects: 119
Study 25935165 — intervention group
Group type: EXPERIMENTAL
Intervention: Early atrial tachycardia (EAT) within 3 months post-procedure
Number of subjects: 119
Study 25935165 — intervention group
Group type: EXPERIMENTAL
Intervention: EAF late in the blanking period (after month 2)
Number of subjects: 119
Study 25935165 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure time
Number of subjects: 119
Study 23094597 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 347
Study 23094597 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 347
Study 22288296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg/day
Number of subjects: 106
Study 22288296 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 2.5 mg/day
Number of subjects: 106
Study 22288296 — intervention group
Group type: COMPARATOR
Intervention: Comparison of nebivolol vs ramipril
Number of subjects: 106
Study 22288296 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 106
Study 20108648 — intervention group
Group type: EXPERIMENTAL
Intervention: 333 mg acamprosate calcium
Number of subjects: 12
Study 20108648 — intervention group
Group type: EXPERIMENTAL
Intervention: 666 mg acamprosate calcium
Number of subjects: 12
Study 20108648 — intervention group
Group type: EXPERIMENTAL
Intervention: 1332 mg acamprosate calcium
Number of subjects: 12
Study 17007600 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality-targeted interventions (group format; 2 sessions)
Number of subjects: 297
Study 17007600 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 297
Study 15532212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula airflow and oximetry monitoring (RDIFlowNPSG)
Number of subjects: 66
Study 15532212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula airflow and oximetry monitoring (RDIFlowAmbulatory)
Number of subjects: 66
Study 15532212 — intervention group
Group type: COMPARATOR
Intervention: Full nocturnal polysomnography (RDIFullNPSG)
Number of subjects: 66
Study 15532212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula airflow from NPSG
Number of subjects: 66
Study 15532212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula airflow from ambulatory study
Number of subjects: 66
Study 11099991 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) or flutter
Number of subjects: 13858
Study 11099991 — intervention group
Group type: COMPARATOR
Intervention: No atrial fibrillation (AF) or flutter
Number of subjects: 13858
Study 9156638 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine 0.02%
Number of subjects: 59
Study 9156638 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine 1.0%
Number of subjects: 59
Study 9156638 — intervention group
Group type: COMPARATOR
Intervention: Buffered saline solution (BSS)
Number of subjects: 59
Study 8329904 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg fentanyl added to 20 ml of 0.5% bupivacaine
Number of subjects: 80
Study 8329904 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 μg fentanyl added to 20 ml of 0.5% bupivacaine
Number of subjects: 80
Study 8329904 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg fentanyl added to 20 ml of 0.5% bupivacaine
Number of subjects: 80
Study 8329904 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study 3533128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg daily
Number of subjects: 11
Study 3533128 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (Inderal LA 160 mg daily)
Number of subjects: 11
Study 3533128 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Nitrendipine and Propranolol)
Number of subjects: 11
Study 29232323 — intervention group
Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 1070
Study 29232323 — intervention group
Group type: COMPARATOR
Intervention: White participants
Number of subjects: 1070
Study 27436797 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-adaptive selection of adjustment set using cross-validation and TMLE
Number of subjects: 32
Study 27436797 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative procedure for estimating known exposure mechanism
Number of subjects: 32
Study 26338457 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHAG + E2 (0.075 mg/d)
Number of subjects: 45
Study 26338457 — intervention group
Group type: COMPARATOR
Intervention: GnRHAG + PL
Number of subjects: 45
Study 22988042 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Health Enhancement Support System + Clinician Report
Number of subjects: 235
Study 22988042 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive Health Enhancement Support System‐Only
Number of subjects: 235
Study 21038017 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher trigeminal component odorants
Number of subjects: 0
Study 21038017 — intervention group
Group type: COMPARATOR
Intervention: Low, middle, high trigeminal component odorants
Number of subjects: 0
Study 18429773 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil cream (70% lanolin, 30% olive oil)
Number of subjects: 173
Study 18429773 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-in-oil emollient cream (Bepanthen)
Number of subjects: 173
Study 18429773 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 173
Study 16643541 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based formula
Number of subjects: 14
Study 16643541 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-based formula
Number of subjects: 14
Study 16643541 — intervention group
Group type: COMPARATOR
Intervention: Formulas containing only lactose
Number of subjects: 14
Study 16643541 — intervention group
Group type: EXPERIMENTAL
Intervention: Special formulas containing non-milk extrinsic sugar
Number of subjects: 14
Study 11978257 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart stickers that prompted physicians to calculate a score based on clinical findings and provided management recommendations linked to score totals
Number of subjects: 621
Study 11978257 — intervention group
Group type: COMPARATOR
Intervention: Clinical checklist
Number of subjects: 621
Study 10319057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 2 mg daily
Number of subjects: 27
Study 10319057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7611579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion to reduce mean arterial blood pressure to 50 mmHg
Number of subjects: 20
Study 7611579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SNP infusion)
Number of subjects: 20
Study 7611579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion
Number of subjects: 20
Study 2229529 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine, 125 mg twice daily
Number of subjects: 28
Study 2229529 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin, 250 mg twice daily
Number of subjects: 28
Study 322607 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin 200 mg
Number of subjects: 66
Study 322607 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin 400 mg
Number of subjects: 66
Study 322607 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin 800 mg
Number of subjects: 66
Study 322607 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 500 mg
Number of subjects: 66
Study 322607 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin (all doses)
Number of subjects: 66
Study 322607 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin
Number of subjects: 66
Study 31542304 — intervention group
Group type: EXPERIMENTAL
Intervention: Galeterone
Number of subjects: 73
Study 31542304 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 73
Study 30012675 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG (2.5 mg/kg intravenously) followed by pegylated GCSF (6 mg subcutaneously every 2 weeks for 6 doses)
Number of subjects: 89
Study 30012675 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG (2.5 mg/kg) alone
Number of subjects: 89
Study 30012675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 27718847 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks)
Number of subjects: 305
Study 27718847 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice of platinum-based chemotherapy)
Number of subjects: 305
Study 27718847 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 305
Study 27718847 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 305
Study 25201708 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/d carnosine for 14 days
Number of subjects: 14
Study 25201708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 23089216 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen and Symphytum 5CH
Number of subjects: 117
Study 23089216 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen alone
Number of subjects: 117
Study 20650624 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 weeks ER (CHF‐ER)
Number of subjects: 57
Study 20650624 — intervention group
Group type: COMPARATOR
Intervention: 7 weeks usual care (CHF‐UC)
Number of subjects: 57
Study 20650624 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 weeks ER (COPD‐ER)
Number of subjects: 57
Study 17909514 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond Solo
Number of subjects: 56
Study 17909514 — intervention group
Group type: COMPARATOR
Intervention: Delton
Number of subjects: 56
Study 17909514 — intervention group
Group type: COMPARATOR
Intervention: Delton Plus
Number of subjects: 56
Study 17909514 — intervention group
Group type: COMPARATOR
Intervention: Concise
Number of subjects: 56
Study 16331772 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 471
Study 16331772 — intervention group
Group type: EXPERIMENTAL
Intervention: New or worsening back pain
Number of subjects: 471
Study 16331772 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe back pain
Number of subjects: 471
Study 11932266 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (DHT) gel, administered transdermally for 6 months, dosage varied from 125-250 mg/d
Number of subjects: 120
Study 11932266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 11932266 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (DHT) gel
Number of subjects: 120
Study 9861112 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg
Number of subjects: 10
Study 8846803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg q.i.d.)
Number of subjects: 0
Study 8846803 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg t.i.d.)
Number of subjects: 0
Study 8846803 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (mean 329 mg per day)
Number of subjects: 0
Study 8846803 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg per day)
Number of subjects: 0
Study 8846803 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose verapamil
Number of subjects: 0